Alentis Therapeutics gains FDA IND approval for ALE.P02, an innovative CLDN1-ADC targeting the treatment of squamous cell cancers.

The FDA has authorized the use of Opdivo® (nivolumab) with chemotherapy before surgery and as a post-surgery treatment for resectable NSCLC.

This partnership will investigate the combined use of casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, and volrustomig.

The SC formulations of TALVEY® (talquetamab) and DARZALEX® (daratumumab) exhibit significant and lasting effects in relapsed or refractory multiple myeloma patients.

Dupixent is the pioneering biologic drug sanctioned in the United States for the treatment of these patients.

The FDA has given the green light to Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a unique muscarinic agonist for adult schizophrenia treatment.

AbbVie Reveals Promising Phase 3 TEMPO-1 Trial Results for Tavapadon as a Solo Parkinson’s Therapy.

Merck to Showcase Extended Data on Tulisokibart (MK-7240), a Trial Anti-TL1A Monoclonal Antibody, in IBD at UEG Week 2024.

Capstan Therapeutics will showcase preclinical findings on their lead in vivo CAR-T candidate, CPTX2309, at the 2024 ACR Convergence.

Enanta Pharmaceuticals Reveals Encouraging Phase 2a Results for EDP-323 in Healthy Adults Challenged with RSV.

enGene Holdings Advances in Clinical-Stage Genetic Medicine with Key Study on Non-Viral Therapy for High-Risk Bladder Cancer.

Sage Therapeutics, Inc. (NASDAQ: Sage) disclosed that Biogen has relinquished its rights under the collaboration and license deal with Sage concerning the SAGE-324 program.